300551-49-9

Basic information

• Product Name: 1(R)-[4-[4-(4,6-Dimethyl-1,3,5-triazin-2-yl)-2(R),6(S)-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol
• CAS NO: 300551-49-9
• Molecular Formula: C₁₇H₂₅N₇O
• Molecular Weight: 343.4351
• Mol File: 300551-49-9.mol

Chemical Properties

• CAS DataBase Reference: 1(R)-[4-[4-(4,6-Dimethyl-1,3,5-triazin-2-yl)-2(R),6(S)-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1(R)-[4-[4-(4,6-Dimethyl-1,3,5-triazin-2-yl)-2(R),6(S)-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol(300551-49-9)
• EPA Substance Registry System: 1(R)-[4-[4-(4,6-Dimethyl-1,3,5-triazin-2-yl)-2(R),6(S)-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol(300551-49-9)

Safety Data

• Hazardous Substances Data: 300551-49-9(Hazardous Substances Data)

Usage

Class

Phosphodiesterase type 5 (PDE5) inhibitors

Function

Treats erectile dysfunction by increasing blood flow to the penis during sexual stimulation

Mechanism of action

Blocks the action of phosphodiesterase-5 enzyme, which regulates blood flow in the penis

Form

Tablet

Administration

Taken as needed, about 25 to 60 minutes before sexual activity

Common side effects

Headache, flushing, stuffy or runny nose, dizziness

Precautions

Consult with a healthcare professional before use to determine if it is the right treatment for erectile dysfunction, discuss potential side effects, and consider drug interactions

Chemical structure

1(R)-[4-[4-(4,6-Dimethyl-1,3,5-triazin-2-yl)-2(R),6(S)-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol

Upstream product

• 474099-97-3 2-{(3S,5R)-4-[2-((R)-1-Butoxy-ethyl)-pyrimidin-4-yl]-3,5-dimethyl-piperazin-1-yl}-4,6-dimethyl-[1,3,5]triazine 
• 474099-93-9 2-{(3S,5R)-4-[2-((R)-1-Butoxy-ethyl)-pyrimidin-4-yl]-3,5-dimethyl-piperazin-1-yl}-4-methyl-6-trichloromethyl-[1,3,5]triazine 
• 300553-35-9 1R-{4-[4-(4-Methyl-6-trichloromethyl-[1,3,5]triazin-2-yl)-2R,6S-dimethyl-piperazin-1-yl]-pyrimidin-2-yl}-ethyl butyrate 

Relevant articles and documents

Sorbitol dehydrogenase inhibitors

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2and R3are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

A sorbitol dehydrogenase inhibitor of exceptional in vivo potency with a long duration of action: 1-(R)-{4-[4-(4,6-dimethyl[1,3,5]triazin-2-yl)-2R, 6S-dimethylpiperazin-1-yl]pyrimidin-2-yl}ethanol

We report here a novel sorbitol dehydrogenase inhibitor, 16, that shows very high oral potency (50 μg/kg) in normalizing elevated fructose levels in the sciatic nerve of chronically diabetic rats and sustained duration of action (>24 h). Furthermore, 16 s